The oropharynx is both the reservoir where antibiotic-resistant Streptococcus pneumoniae strains are selected and the focus for further spread of these organisms. In order to select antibiotic-resistant organisms, the antibiotic must be able to eradicate the susceptible population. How an antibiotic acts on oropharyngeal flora is not fully understood, although data on salivary antibiotic concentrations could be useful for establishing some correlation. Many β-lactam antibiotics are very active against S. pneumoniae, and although their saliva concentrations are very low, there may be enough to eradicate the majority of β-lactam-sensitive strains. Other antibiotics achieve salivary concentrations in the range 10-30% of serum concentrations (erythromycin, clindamycin, doxycycline and rifampicin), and are also able to eradicate the antibiotic-susceptible population. Antibiotics achieving higher salivary concentrations (≥40% of the serum levels) are not very active against S. pneumoniae (ciprofloxacin) or are able to eradicate antibiotic-sensitive and -intermediate strains (clarithromycin, azithromycin and telithromycin). Only antibiotics for which there are no highly resistant pneumococcal strains, for instance some β-lactams administered at very high dose and for a short course, are associated with a lower risk of antibiotic resistance selection. To diminish the risk, the antibiotics should be dosed in order to obtain inhibitory quotients (maximal serum concentration/MIC ratios) ≥ 4, which depends not only on the antibiotic concentration achieved but also on the lack of highly resistant organisms.
Introduction
Many surveillance studies have shown the presence of Streptococcus pneumoniae in the nasopharynx of healthy individuals, particularly children. As the nasopharynx can be the port of entry for mucosal and invasive infections, carriage can lead to pneumococcal diseases such as otitis media, sinusitis, pneumonia, sepsis and meningitis. Transmission from person to person is frequent, particularly in certain settings such as day-care centres and among household members. Persistent carriage of pneumococcal strains harbouring antibiotic resistance genes may promote the development and spread of resistance. Antibiotic therapy of resistant pneumococcal infections can fail in terms of achieving bacterial eradication, which may pose a wide epidemiological problem.
When antibiotic therapy is administered, the drug may reach the infectious foci, but it is also distributed to other body compartments, selecting resistant organisms not only in the nasopharynx but also in other normally colonized areas. Many antibiotics are able to eradicate susceptible pneumococci from the nasopharynx, creating an ecological vacuum, which is then occupied by other bacteria that may have a different antimicrobial susceptibility pattern. The selection of antibiotic-resistant S. pneumoniae in the nasopharynx is affected by the nature of the previous bacterial flora, the antibiotic class, dosage and treatment duration.
Pharmacokinetics of antibiotics and penetration into saliva
The penetration of antibiotics in the nasopharyngeal mucosa is a very complex process in which the presence of inflammation and antibiotic pharmacokinetic properties are important factors. If an inflammatory reaction occurs, the penetration of most antibiotics into the infectious foci is improved, and this facilitates bacterial eradication. Conversely, if inflammation is absent, as in the normal oropharynx, drug penetration is generally poor. This is the case in antibiotic action against nasopharyngeal carriage of S. pneumoniae. Antibiotics, after oral or parenteral administration, can be transported from blood to saliva by simple diffusion and/or active transport mechanisms. 1 Depending upon the degree of ionization, antibiotics that are weak bases may reach high concentrations in saliva. Therefore, in the absence of inflammation, the ability of antibiotics to achieve detectable concentrations in saliva depends on their chemical structure. Mostly, the salivary concentrations reflect the intracellular concentration in target tissues. 2 After reviewing published literature on penetration of antibiotics into saliva, we propose to classify them in three groups.
(i) Antibiotics achieving very low concentrations. The concentrations achieved are lower than 10% of serum concentrations and frequently undetectable. 3-11 Most β-lactam antibiotics and sulfamethoxazole can be included in this group (Table 1) .
(ii) Antibiotics achieving moderate concentrations. This group includes antibiotics achieving salivary concentrations in the range 10-30% of serum concentrations. 5,12-16 Erythromycin, clindamycin, doxycycline and rifampicin share this characteristic (Table 2) .
(iii) Antibiotics achieving high concentrations. These antibiotics reach salivary concentrations > 40% of those obtained in serum (ciprofloxacin, clarithromycin, azithromycin, telithromycin and trimethoprim). 6,10,11,17-21 Frequently, the salivary concentrations exceed those achieved in serum (azithromycin, telithromycin and trimethoprim) ( Table 3) .
Impact of antibiotics on the nasopharyngeal flora
A number of studies have been published dealing with the impact of antibiotics on the nasopharyngeal flora in both healthy volunteers and children with acute otitis media (AOM) treated with different antibiotics. The paediatric studies have evaluated not only clinical and bacteriological efficacy but also the antibiotic effect on the nasopharyngeal carriage of S. pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. The available information allows us to classify antibiotics in the following three groups.
(i) Antibiotics causing very little impact on the pharyngeal flora. This group includes most β-lactam antibiotics (penicillin V, ampicillin, amoxicillin, co-amoxiclav, cefuroxime, 30 caused a temporary suppression of viridans streptococci. Although ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin and levofloxacin achieve high concentrations in saliva, they have only little or no effect on the nasopharyngeal flora. 27, 31, 32 This is probably due to their low in vitro activity on the flora monitored.
(ii) Antibiotics causing a moderate impact on the pharyngeal flora. Doxycycline, erythromycin, clarithromycin and telithromycin can be included in this group. Doxycycline and erythromycin decrease the number of streptococci with little or no appreciable effect on the anaerobic flora. 24 Clarithromycin and telithromycin produce moderate suppression of aerobic coryneforms, Actinomyces spp. and Prevotella spp. 33 Transient colonization by Candida spp. and Enterobacteriaceae were also observed, as well as the emergence of highly clarithromycin-resistant viridans streptococci after administration of this antibiotic. 33 (iii) Antibiotics causing the greatest impact on the pharyngeal flora. Clindamycin affects the number of streptococci and greatly reduces the anaerobic flora. 24 Other antibiotics, including β-lactams, administered at high dose or for prolonged periods can reduce the number of viridans streptococci, staphylococci and Neisseria spp. 22, 25, 27, 29, 30 Although saliva coats the nasopharyngeal epithelial surface where bacteria are mostly located, it has not been shown whether penetration of antibiotics into saliva is associated with the antibiotic effect on nasopharyngeal carriage. Nevertheless, the data do indicate a direct, although imperfect, correlation between antibiotic concentration in saliva and impact on the pharyngeal flora.
Pharmacodynamic considerations of the process of resistance selection
Antibiotics that are active in vitro against S. pneumoniae reduce the nasopharyngeal colonization rate in most individuals. However, they exert a different impact in the case of antibiotic-resistant pneumococcal carriage. Amoxicillin, co-amoxiclav, cefpodoxime, cefuroxime and cefixime predominantly eradicate penicillin-susceptible strains, and consequently, the penicillin-insensitive (intermediate and resistant) strains are selected and increased. [34] [35] [36] [37] [38] The eradication rate of penicillin-susceptible strains has been described as >50% with β-lactam antibiotics, but the eradication rate for penicillin-non-susceptible strains has ranged from 27% to 75% for penicillin-intermediate and from 0% to 40% for penicillin-resistant strains. 36,37 A single dose of ceftriaxone administered to children achieves a high eradication rate of penicillin-susceptible S. pneumoniae, but it selects for penicillin-resistant ones. 22,39 Although β-lactams are usually very active in vitro against S. pneumoniae, their low concentration achieved in saliva may be responsible for eradicating penicillin-susceptible strains only. The intrinsic activity of antibiotics also plays a fundamental role in their ability to eradicate nasopharyngeal pneumococci. For instance, comparison of cefuroxime axetil versus cefaclor therapy demonstrated a higher eradication rate by the former agent in a paediatric trial. 36 Amoxicillin, coamoxiclav and cefpodoxime have shown higher eradication rates than those of cefaclor, cefuroxime or cefixime. 35, 40 Cefixime is one of the β-lactam antibiotics more often associated with a high rate of resistance development. 35, 41 In vitro models have also shown that oral cephalosporins appear to be more potent selectors of penicillin-non-susceptible strains than penicillin and aminopenicillins. 42 During the early 1990s in France, there was a shift from oral aminopenicillins toward oral cephalosporin therapy for respiratory tract infections. Afterwards, an increase in penicillin-resistant S. pneumoniae strains was observed, which may be explained by the different pharmacokinetic/pharmacodynamic characteristics of the two drug classes. 43 Macrolide antibiotics can also eliminate susceptible pneumococcal strains, and thus, select and increase macrolide-resistant carriage, particularly of highly resistant strains. 36,37,40,44,45 Penicillin-and macrolide-resistant strains can be selected by any of these antibiotics. Indeed, the use of one antibiotic selects for resistance to more than one antibiotic; for instance, administration of β-lactams may select not only for penicillin resistance but also for macrolide and co-trimoxazole resistance. Table 4 presents results of penicillin and clarithromycin activity against S. pneumoniae [unpublished data based on the Antibiotic Resistant Isolates in Southern Europe (ARISE) project]. Strains not susceptible to penicillin and clarithromycin were found in 33% and 35%, respectively, of the 877 organisms isolated from adult patients in four southern European countries. A penicillin concentration of 0.06 mg/L eliminated up to 67% of the strains and selected for penicillin-non-susceptible strains, but the percentage of clarithromycin-non-susceptible strains increased from 35% to 63%. Similarly, a clarithromycin concentration of 2 mg/L eliminated up to 68% of the strains and selected for clarithromycin-resistant strains, but the percentage of penicillin-non-susceptible strains increased from 33% to 59%.
Co-trimoxazole usage selects for strains resistant to this compound but also for penicillin-resistant ones. 46, 47 Drugs that are inactive against many pneumococci, such as sulfisoxazole, do not select for antibiotic-resistant strains. 38 The reverse of this phenomenon has been observed in Iceland where a reduction in prescriptions for macrolides and cotrimoxazole led to a decrease in penicillin-non-susceptible isolates. 48 From the pharmacodynamic point of view, the main factor associated with antibiotic resistance selection is the exposure of microorganisms to subinhibitory concentrations of anti- biotics for prolonged periods. For β-lactams, it has been shown that children treated with low daily doses of oral antibiotics had an increased risk for penicillin-resistant S. pneumoniae carriage, as compared with children who were not (OR = 5.9). 49 Also, treatment of long duration (>5 days) with a β-lactam antibiotic was associated with an increased risk of penicillin-resistant pneumococcal carriage (OR = 3.5). 49 This strategy has been successfully documented in a recent randomized trial in children with respiratory tract infections. Shortcourse, high-dose amoxicillin therapy (90 mg/kg/day for 5 days) was compared with a standard regimen (40 mg/kg/day for 10 days). At the day 28 follow-up, the short-course, highdose regimen correlated with lower risk of penicillin-nonsusceptible pneumococcal carriage (24% versus 32%; relative risk 0.77, P = 0.03). 50 Guillemot et al. 51 have recently conducted a comparative population-based epidemiological trial to study the impact of two strategies of antibiotic use on penicillin-non-susceptible S. pneumoniae oropharyngeal carriage. The first intervention aimed to reduce the use of antibiotics (group 1, n = 943), and the second one to improve the dose and reduce the antibiotic duration (group 2, n = 818) for upper respiratory tract infections in children aged 3-6 years. The third group (n = 664) received no intervention, and were used as controls. Evolution of penicillin-non-susceptible S. pneumoniae rates in the three groups was different. Monthly linear trend in each group, estimated by the ρ regression coefficient of the rates on time, was significantly different from zero: ρ = -1.5% (P = 0.05) in group 1, ρ = -2% (P = 0.04) in group 2, whereas no decrease was observed in group 3, ρ = 0% (P = 0.9). Therefore, a 2% monthly decrease in the rate of penicillin-nonsusceptible pneumococcal carriage (10% in 5 months for group 1) was achieved after implementing strategies to improve the use of antibiotics. 51 In individuals carrying S. pneumoniae, clarithromycin or azithromycin therapy may cause bacteria to be exposed to subinhibitory concentrations for long periods (up to 3 weeks) until the antibiotic is totally eliminated from the body. All this increases the potential for development of resistance. 52 Analysis of the Alexander Project data 53 revealed a correlation between the use of long-acting macrolides (azithromycin and clarithromycin) and the prevalence of macrolideresistant S. pneumoniae, although no correlation was found with short-acting macrolides. Different potency and pharmacokinetics of antibiotics may explain different potentials for the selection of resistant clones. Alternatively, this correlation may result in a threshold in the selective intensity of the total amount of macrolides used in a particular community. 54 To maximize bacterial eradication and minimize the emergence of antibiotic-resistant organisms, penicillins and fluoroquinolones should be dosed in order to achieve serum inhibitory quotients (peak serum concentration/MIC) ≥ 4, while for cephalosporins inhibitory quotients ≥ 16 have been suggested. 55, 56 These targets may allow antibiotic serum concentrations exceeding the MIC of the pathogen for 80-100% of the dosing interval. 57 The low prevalence of penicillinresistant S. pneumoniae strains in Italy, in spite of wide usage of β-lactam antibiotics, has been explained by the predominant use of parenteral versus oral administration, which produces better inhibitory quotients and longer T > MIC exposure, therefore preventing the selection of antibioticresistant mutants.
Taking the pharmacokinetic properties of antibiotics into account, a favourable inhibitory quotient may be obtained for amoxicillin against S. pneumoniae. Contrarily, for fluoroquinolones, cefaclor and cefixime the ratios are less favourable, which confers a greater potential for resistance development during treatment with these agents. 56 
A novel antimicrobial susceptibility parameter, the mutant prevention concentration (MPC), has been proposed for evaluation of both antibiotic activity and ability to prevent the development of resistant pathogens. The MPC has been defined as the minimal antibiotic concentration preventing the growth of resistant single-step mutants when the microorganism is exposed to the antibiotic at a high inoculum (i.e. 10 10 cfu). 58 This concept was initially developed to be applied to Mycobacterium tuberculosis but it may also be applied to other organisms, including S. pneumoniae. In order to reduce the risk of antibiotic resistance selection, the antibiotic MPC and MIC for any pathogen should be very close, which would narrow the window of resistance selection. The MPC could be used as a guide for choosing and eventually administering fluoroquinolones to significantly reduce the development of resistance. 59 The MPC is usually within four to 10 times the MIC of fluoroquinolones for the pathogen. The ratio AUC/ MPC has recently been proposed to express therapeutic concentrations; application of this ratio did not suppress resistance to levofloxacin, although resistance to moxifloxacin did not emerge. 60 The MPC for the killing of pneumococci by several quinolones such as gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin has been reported recently. 61 The rapid reduction in viable bacteria at antimicrobial concentrations exceeding the MPC may have an impact on the selection of resistant organisms, and may explain the rapid symptom resolution seen with new fluoroquinolones. 61 Surveillance studies dealing with the impact of antibiotics on the nasopharyngeal flora show that with prolonged followup, such flora normalizes and even the antibiotic-resistant mutants are spontaneously eliminated when the selective pressure of the antibiotic disappears. 45, 62 However, a high level of carriage of antibiotic-resistant S. pneumoniae in the community is associated with a high prevalence of disease caused by this resistant organism. 63 Furthermore, there is a real risk of transmission of antibiotic-resistant strains through individuals colonized by such strains.
In order to decrease the antibiotic-resistant strains, a reduction in, and a more rational use of, antibiotics should be encouraged. Recent evidence supports the idea that use of short-course, high-dose regimens can be both efficacious and ecologically appropriate, as it reduces the risk of antibiotic resistance selection. 
